Analysts See $-0.51 EPS for ADMA Biologics, Inc. (ADMA); SEMICONDUCTOR MANUFACTURING INTE (SIUIF) SI Increased By 6.1%

February 15, 2018 - By Russell Anderson

SEMICONDUCTOR MANUFACTURING INTE (OTCMKTS:SIUIF) had an increase of 6.1% in short interest. SIUIF’s SI was 67.83 million shares in February as released by FINRA. Its up 6.1% from 63.94M shares previously. With 100 avg volume, 678349 days are for SEMICONDUCTOR MANUFACTURING INTE (OTCMKTS:SIUIF)’s short sellers to cover SIUIF’s short positions. The stock increased 1.71% or $0.02 during the last trading session, reaching $1.19. About shares traded. Semiconductor Manufacturing International Corporation (OTCMKTS:SIUIF) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect ADMA Biologics, Inc. (NASDAQ:ADMA) to report $-0.51 EPS on February, 23.They anticipate $0.16 EPS change or 45.71% from last quarter’s $-0.35 EPS. After having $0.59 EPS previously, ADMA Biologics, Inc.’s analysts see -186.44% EPS growth. The stock increased 1.77% or $0.07 during the last trading session, reaching $4.02. About 58,916 shares traded. ADMA Biologics, Inc. (NASDAQ:ADMA) has declined 37.56% since February 15, 2017 and is downtrending. It has underperformed by 54.26% the S&P500.

Semiconductor Manufacturing International Corporation, an investment holding company, engages in the computer-aided design, manufacture, testing, packaging, and trading of integrated circuits and other semiconductor services. The company has market cap of $5.14 billion. It also creates and makes semiconductor masks; and makes and trades in solar cell related semiconductor products. It has a 22.88 P/E ratio. In addition, the firm is involved in the bumping and circuit probe testing, as well as marketing related activities.

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ADMA Biologics had 8 analyst reports since September 9, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by Raymond James on Monday, August 1. The firm earned “Buy” rating on Monday, January 23 by Maxim Group. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) earned “Outperform” rating by Raymond James on Tuesday, November 14. The firm earned “Hold” rating on Monday, August 1 by Maxim Group. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) has “Buy” rating given on Wednesday, June 28 by Maxim Group. Raymond James initiated ADMA Biologics, Inc. (NASDAQ:ADMA) rating on Wednesday, September 9. Raymond James has “Strong Buy” rating and $15 target. The firm earned “Buy” rating on Thursday, September 17 by Maxim Group. Maxim Group maintained the stock with “Buy” rating in Wednesday, June 7 report.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases. The company has market cap of $182.17 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>